Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2000 Sep;69(3):376–380. doi: 10.1136/jnnp.69.3.376

Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART)

M Maschke 1, O Kastrup 1, S Esser 1, B Ross 1, U Hengge 1, A Hufnagel 1
PMCID: PMC1737101  PMID: 10945813

Abstract

OBJECTIVE—To determine the change of incidence and prevalence of neurological disorders caused by the human immunodeficiency virus (HIV) and opportunistic infections in HIV positive patients under treatment since the introduction of highly active antiretroviral therapy (HAART).
METHODS—The data of all HIV infected patients were retrospectively analysed, who were examined in the HIV outpatients clinic of the neurological department of the University Clinic Essen between 1995 and 1998 (n=563, total number of visits=735). Data from identified patients were divided into two groups according to the time of examination from 1995 to 1996 (334 visits) and from 1997 to 1998(401 visits). The incidence and prevalence of neurological disorders were statistically compared between both time intervals.
RESULTS—Significantly more patients received HAART in 1997-8 (p<0.001) and mean CD4+ cell count was significantly higher in 1997-8 (p<0.001). The prevalence of HIV associated dementia and HIV associated polyneuropathy were significantly lower in 1997-8 (both: p=0.02) and the incidence of toxoplasma encephalitis decreased from 5.7% in 1995-6 to 2.2% in 1997-8 (p=0.015). Based on the small number of patients significant changes in HIV associated myopathy, progressive multifocal leukoencephalopathy, cryptoccocal meningitis, and cytomegalovirus-encephalitis could not be detected.
CONCLUSION—The prevalence of the most frequent HIV associated neurological disorders and incidence of toxoplasma encephalitis decreased since the introduction of HAART. This may be due to the improvement of immunostatus by HAART as demonstrated by the higher CD4+ cell count in the later time interval. Direct antiretroviral effects within the nervous system may be considered causative as well. The prevalence and incidence of HIV associated neurological disorders and opportunistic CNS infections decreased after introduction of HAART.



Full Text

The Full Text of this article is available as a PDF (119.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albrecht H., Hoffmann C., Degen O., Stoehr A., Plettenberg A., Mertenskötter T., Eggers C., Stellbrink H. J. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS. 1998 Jul 9;12(10):1149–1154. doi: 10.1097/00002030-199810000-00006. [DOI] [PubMed] [Google Scholar]
  2. Brodt H. R., Kamps B. S., Gute P., Knupp B., Staszewski S., Helm E. B. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 1997 Nov 15;11(14):1731–1738. doi: 10.1097/00002030-199714000-00010. [DOI] [PubMed] [Google Scholar]
  3. Childs E. A., Lyles R. H., Selnes O. A., Chen B., Miller E. N., Cohen B. A., Becker J. T., Mellors J., McArthur J. C. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology. 1999 Feb;52(3):607–613. doi: 10.1212/wnl.52.3.607. [DOI] [PubMed] [Google Scholar]
  4. Clifford D. B., Yiannoutsos C., Glicksman M., Simpson D. M., Singer E. J., Piliero P. J., Marra C. M., Francis G. S., McArthur J. C., Tyler K. L. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology. 1999 Feb;52(3):623–625. doi: 10.1212/wnl.52.3.623. [DOI] [PubMed] [Google Scholar]
  5. Dannemann B., McCutchan J. A., Israelski D., Antoniskis D., Leport C., Luft B., Nussbaum J., Clumeck N., Morlat P., Chiu J. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med. 1992 Jan 1;116(1):33–43. doi: 10.7326/0003-4819-116-1-33. [DOI] [PubMed] [Google Scholar]
  6. Dore G. J., Correll P. K., Li Y., Kaldor J. M., Cooper D. A., Brew B. J. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 1999 Jul 9;13(10):1249–1253. doi: 10.1097/00002030-199907090-00015. [DOI] [PubMed] [Google Scholar]
  7. Gendelman H. E., Zheng J., Coulter C. L., Ghorpade A., Che M., Thylin M., Rubocki R., Persidsky Y., Hahn F., Reinhard J., Jr Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis. 1998 Oct;178(4):1000–1007. doi: 10.1086/515693. [DOI] [PubMed] [Google Scholar]
  8. Girard P. M., Landman R., Gaudebout C., Olivares R., Saimot A. G., Jelazko P., Gaudebout C., Certain A., Boué F., Bouvet E. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. N Engl J Med. 1993 May 27;328(21):1514–1520. doi: 10.1056/NEJM199305273282102. [DOI] [PubMed] [Google Scholar]
  9. Janssen R. S., Cornblath D. R., Epstein L. G., McArthur J., Price R. W. Human immunodeficiency virus (HIV) infection and the nervous system: report from the American Academy of Neurology AIDS Task Force. Neurology. 1989 Jan;39(1):119–122. doi: 10.1212/wnl.39.1.119. [DOI] [PubMed] [Google Scholar]
  10. Janssen R. S., Nwanyanwu O. C., Selik R. M., Stehr-Green J. K. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology. 1992 Aug;42(8):1472–1476. doi: 10.1212/wnl.42.8.1472. [DOI] [PubMed] [Google Scholar]
  11. Levy R. M., Janssen R. S., Bush T. J., Rosenblum M. L. Neuroepidemiology of acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr. 1988;1(1):31–40. [PubMed] [Google Scholar]
  12. Markus R., Brew B. J. HIV-1 peripheral neuropathy and combination antiretroviral therapy. Lancet. 1998 Dec 12;352(9144):1906–1907. doi: 10.1016/s0140-6736(05)60397-2. [DOI] [PubMed] [Google Scholar]
  13. Sacktor N. C., Lyles R. H., Skolasky R. L., Anderson D. E., McArthur J. C., McFarlane G., Selnes O. A., Becker J. T., Cohen B., Wesch J. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology. 1999 May 12;52(8):1640–1647. doi: 10.1212/wnl.52.8.1640. [DOI] [PubMed] [Google Scholar]
  14. Schwartländer B., Horsburgh C. R., Jr, Hamouda O., Skarabis H., Koch M. A. Changes in the spectrum of AIDS-defining conditions and decrease in CD4+ lymphocyte counts at AIDS manifestation in Germany from 1986 to 1991. AIDS. 1992 Apr;6(4):413–420. doi: 10.1097/00002030-199204000-00009. [DOI] [PubMed] [Google Scholar]
  15. So Y. T., Holtzman D. M., Abrams D. I., Olney R. K. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol. 1988 Sep;45(9):945–948. doi: 10.1001/archneur.1988.00520330023005. [DOI] [PubMed] [Google Scholar]
  16. Zhang L., Looney D., Taub D., Chang S. L., Way D., Witte M. H., Graves M. C., Fiala M. Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol. 1998 Dec;4(6):619–626. doi: 10.3109/13550289809114228. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES